On April 23, 2026 Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer efficacy while minimizing toxicity, reported the establishment of a SAB, including world-renowned experts, to advise the Company on the development of candidates from its next-generation CAPTN-3 tri-specific antibody platform. SAB Members:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

● Amir Horowitz, PhD- an expert in natural killer (NK) cell biology and tumor-immune interactions, Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, Icahn School of Medicine at Mount Sinai

● Afshin Dowlati, MD- Professor, Department of Medicine and Associate Director for Clinical Research, Case Comprehensive Cancer Center at Case Western Reserve University with extensive experience in early-phase clinical development of T-cell engager therapies in solid tumors, including DLL3-targeted approaches.

● Alexander Shoushtari, MD- Associate Attending Physician, Melanoma Medical Oncologist and Cellular Therapist at Memorial Sloan Kettering Cancer Center and clinical investigator involved in the development of tebentafusp, one of the first approved T-cell engager therapies in solid tumors.

● Max S. Topp, MD- Head of Hematology and Associate Professor for Translational Immunology at the Universitätsklinikum Würzburg, Germany Medical Clinic who played a key role in the early clinical development of blinatumomab, one of the first approved bispecific T-cell engager therapies.

"The newly established SAB brings together leading experts in T cell and NK engagers development, tumor immunology, and clinical oncology, including clinicians and scientists with direct experience in the development of some of the first approved and foundational therapies in the field. The SAB will provide strategic guidance as Purple advances our CAPTN-3 platform development." said Gil Efron, Chief Executive Officer of Purple Biotech. "CAPTN-3 represents a differentiated approach to immunotherapy, combining conditional activation with multi-mechanism immune engagement. As we advance toward clinical development, we believe it is critical to bring together advisors with deep expertise across both the biology and clinical dimensions of T-cell engagers. We are pleased to assemble a group with direct experience in developing and advancing these types of therapies into the clinic."

SAB Biographies

Amir Horowitz, PhD is an Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. His research focuses on harnessing NK and CD8 T cells for antitumor effector functions and has demonstrated a novel immunotherapeutic target axis involving the interaction between HLA-E expressing tumor cells and NKG2A-positive NK and CD8 T cells, which suppresses immune responses in treatment-resistant patients. Dr. Horowitz and others have demonstrated that the HLA-E/NKG2A axis is a dominant inhibitory checkpoint pathway in solid tumors and metastasis.

Afshin Dowlati, MD, is an expert in the biology and clinical management of thoracic malignancies and has led the thoracic oncology program at Case Western Reserve University since 2000. His work bridges clinical practice and translational research, with a focus on target validation and drug development, and he is uniquely positioned to advance novel therapeutics from preclinical models into the clinic. A major focus of Dr. Dowlati’s research is small cell lung cancer (SCLC), an area where progress has been limited due to an incomplete understanding of disease biology. He has established a robust research infrastructure, including a retrospective clinical-pathologic database of over 800 SCLC patients treated at his institution over more than 15 years. This resource is complemented by genomic and transcriptomic data, enabling identification of clinically relevant mutations associated with survival and treatment response. His team utilizes cell line and mouse models to investigate these genomic drivers and generate data to support future clinical trials. He is also a founding member of an SCLC consortium dedicated to advancing research and treatment in this field, and has recently initiated efforts to define molecular predictors of response to immune checkpoint inhibitors in SCLC.

Alexander Shoushtari, MD, is a highly regarded medical oncologist based in New York, New York. He specializes in treating melanoma, particularly acral, mucosal, and uveal types, and is known for his expertise in cell- and immune-based therapies. Dr. Shoushtari has extensive experience in various oncology fields and is Associate Attending Physician at Memorial Sloan Kettering Cancer Center, where he has the largest practice for treating patients with melanoma. He is also an Assistant Attending Physician at the same institution, where he focuses on melanoma treatment and research. Dr. Shoushtari is a board-certified medical oncologist and has been in practice for over 15 years, offering a wealth of knowledge and experience to his patients.

Max S. Topp, MD, is head of haematology and associate Professor for translational immunology at the medical clinic II at the Universitätsklinikum Würzburg, Germany. After completing his medical degree at the University of Berlin, Germany, he undertook residencies at the Free University of Berlin and the University of Tübingen, both in Germany, and a postdoctoral fellowship in immunotherapy at the Fred Hutchinson Cancer Research Center in Seattle, USA. He is board certified in internal medicine and hematology/oncology and was appointed as Associated Professor for Translational Immunology in 2011 and Head of Hematology in 2014 at the Universitätsklinikum Würzburg. Professor Topp’s research interests are in immunotherapy, both bispecific antibody constructs and CAR-T cells of leukemia and lymphomas. In addition, he has been the principal investigator in numerous trials for acute lymphoblastic leukemia, Hodgkin’s lymphoma and diffuse large B-cell lymphoma. He is also a steering committee member of the German ALL Study Group and the German Hodgkin Lymphoma Study Group.

About the CAPTN-3 Platform

CAPTN-3, Purple Biotech’s lead program, is a platform of masked tri-specific antibodies that simultaneously target tumor-associated antigens while engaging both T cells and NK cells. Proprietary capping technology confines immune activation to the tumor microenvironment by masking the CD3-binding arm in circulation and activating it only at the tumor site, significantly expanding the therapeutic window versus unmasked T-cell engagers. The platform’s lead candidates, IM1240 (targeting 5T4) and IM1305 (targeting TROP2), are in preclinical development.

(Press release, Purple Biotech, APR 23, 2026, View Source [SID1234664725])

On April 23, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported the presentation of new preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026 highlighting the potential of its lead drug candidate, Annamycin, in pancreatic cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are highly encouraged by these results, which demonstrate compelling anti-tumor activity in pancreatic cancer models. Importantly, these findings are consistent with the effects we continue to observe with Annamycin in AML," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "This consistency across both hematologic and solid tumor settings reinforces our confidence in Annamycin’s underlying mechanism."

"It is important to highlight that the clinical landscape continues to reflect the trend toward increased use of combination therapies, especially those that combine innovative targeted mechanisms with time-tested cytotoxic payloads. It’s in these settings that Annamycin’s potential may be at its greatest considering its lack of cardiotoxicity, greater tolerability and ability to avoid resistance mechanisms. We believe these data underscore Annamycin’s potential to expand into additional high-need cancer indications," added Mr. Klemp

The data demonstrate that liposomal Annamycin (L-ANN), a novel, non-cardiotoxic anthracycline, produced significant tumor growth inhibition across multiple pancreatic ductal adenocarcinoma (PDAC) models, including orthotopic human PDAC and syngeneic systems, with strong statistical significance (p < 0.001). These findings were accompanied by a meaningful survival benefit in a metastatic model, where treatment extended median survival by more than 60% compared to control (29 days versus 18 days; p = 0.0003), underscoring the potential clinical relevance of L-ANN in aggressive disease settings.

Pharmacokinetic analyses further demonstrated enhanced tumor penetration and retention of Annamycin compared to doxorubicin, with significantly higher accumulation observed in pancreatic tissue and tumors (p<0.0001). These data provide a mechanistic basis for the observed anti-tumor activity and highlight a key differentiating feature of Annamycin relative to traditional anthracyclines, which have historically shown limited efficacy in pancreatic cancer.

In addition to its direct cytotoxic effects, L-ANN was shown to induce immune activation within the tumor microenvironment, including increased infiltration of CD8+ cytotoxic T cells and CD4+ helper T cells. These findings suggest the potential for Annamycin to convert immunologically "cold" pancreatic tumors into more responsive phenotypes, supporting its evaluation both as a monotherapy and in combination with other drugs, including immune checkpoint and KRAS inhibitors.

Consistent with prior studies, Annamycin also demonstrated a favorable safety profile, including the absence of cardiotoxicity, a well-documented limitation of conventional anthracyclines such as doxorubicin. This differentiated safety profile may enable broader therapeutic use and synergistic combination strategies.

The Company is currently evaluating Annamycin in combination with cytarabine (Ara-C), collectively referred to as AnnAraC, in its pivotal Phase 2B/3 "MIRACLE" trial for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) following induction therapy. The MIRACLE trial is a global, adaptive Phase 2B/3 clinical study being conducted across the United States, Europe, and other international sites.

These data were presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026.

(Press release, Moleculin, APR 23, 2026, View Source [SID1234664724])

On April 23, 2026 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, reported its sales for the first quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Q1 2026 % change % change
€m Actual CER
Oncology 707.5 8.0 % 13.0 %
Rare Disease 147.1 109.1 % 125.4 %
Neuroscience 220.3 13.8 % 18.5 %
Total Sales 1,074.9 17.0% 22.6%

"Ipsen has delivered a strong start to 2026," said David Loew, Chief Executive Officer, Ipsen. "We advanced our strategic priorities across the business, combining strong top‑line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients."

Full-year guidance 2026
Ipsen is confirming its financial guidance3 for full-year 2026:

Total sales growth greater than 13.0%, at constant currency, assuming accelerated sales growth of the portfolio excluding Somatuline and the growth of Somatuline sales due to generic lanreotide challenges. Based on the average level of exchange rates in March 2026, an adverse effect on total sales of around 1% of currencies is expected
Core operating margin greater than 35.0% of total sales
Upcoming 2026 milestones

Ipsen anticipates several key milestones across its portfolio in 2026, including:

Iqirvo (ELSPIRE trial) – Readout of pivotal Phase III in primary biliary cholangitis
Bylvay (BOLD trial) – Readout of pivotal Phase III in biliary atresia
Dysport (BEOND trials) – Readout of pivotal Phase III trials in chronic and episodic migraine
Corabotase (IPN10200, LANTIC trial) – Readout of Phase II in lateral canthal lines and forehead lines
Data from stage 1 of the Phase II LANTIC trial of corabotase (IPN10200) will be presented at the Music City SCALE (Symposium for Cosmetic Advances and Laser Education) 2026 symposium in May.

Pipeline update
On 30 January 2026, Ipsen expanded its pre‑clinical pipeline in rare neurodegenerative diseases through a global collaboration and exclusive option agreement with Origami Therapeutics. The partnership focuses on a research‑stage protein‑degrader program targeting genetic neurodegenerative diseases. Should Ipsen exercise its option following successful drug‑candidate nomination, the Company would assume full responsibility for global development and commercialization, reinforcing its strategy in rare neuroscience and first‑in‑class innovation.

On 9 March 2026, Ipsen announced the voluntary withdrawal of Tazverik (tazemetostat) from all indications and all Ipsen markets, effective immediately, following emerging safety data from the ongoing Phase Ib/III SYMPHONY‑1 trial in follicular lymphoma.

On 22 April 2026, following the positive European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion, Ipsen was granted conditional marketing authorization by the European Commission (EC) for Ojemda (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. Approval is based on the pivotal Phase II FIREFLY-1 data demonstrating meaningful and durable tumor responses.

Conference call

A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here; webcast details can be found here.

Calendar

Ipsen intends to publish its half-year results on 30 July 2026.

Notes

All financial figures are in € millions (€m). The performance shown in this announcement covers the three-month period to 31 March 2026 (Q1 2026, the quarter), compared to the three-month period to 31 March 2025 (Q1 2025) unless stated otherwise.

(Press release, Ipsen, APR 23, 2026, View Source [SID1234664722])

On April 23, 2026 Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, reported that an abstract has been accepted for publication at the upcoming 2026 ASCO (Free ASCO Whitepaper) Annual Meeting along with a corresponding poster presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 2026 ASCO (Free ASCO Whitepaper) Annual Meeting will be held from May 28 to June 2, 2026. The full text of the abstract and poster will be available on June 1, 2026, the day of the presentation.

CEO Snehal Patel commented, " We look forward to meeting many of our principal investigators at the conference. Our abstract will be the second abstract co-authored by the Company and the full Steering Committee of FLAMINGO-01 presenting preliminary injection site reaction immune response data from the non-HLA-A*02 open-label arm."

In addition to ASCO (Free ASCO Whitepaper), the Company plans to attend ESMO (Free ESMO Whitepaper) Breast, BIO partnering, and investor conferences in the coming months.

About the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting

ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO (Free ASCO Whitepaper) offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide. The ASCO (Free ASCO Whitepaper) Annual Meeting program features poster presentations, poster discussion sessions, clinical science symposia, and dynamic education sessions about recent advancements in cancer research, treatment, and patient care. For more information, please visit the conference website at: View Source

About FLAMINGO-01 Open Label Phase III Data

More than 1,300 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
The AACR (Free AACR Whitepaper) Meeting 2026 delayed-type-hypersensitivity (DTH) poster can be downloaded here.
The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, p < 0.001).
As reported in Table 1 of the poster, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline with frequency increasing from 100% to 700%.
Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100. Baseline immune response to GP2 prior to any vaccination with GP2 was also observed in the Phase IIb trial and is being observed in the blinded randomized arms of FLAMINGO-01, where HLA-A*02 only patients are being vaccinated.
Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:

80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
The PIS elicited a potent immune response as measured by local skin tests and immunological assays.
About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the "Contacts and Locations" section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

(Press release, Greenwich LifeSciences, APR 23, 2026, View Source [SID1234664721])

On April 23, 2026 Epitopea, a transatlantic biotech developing off-the-shelf, durable, RNA-based cancer immunotherapies, reported that it has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Regional Ethics Committee (REC) for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of its lead program, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epitopea also announces the appointment of Professor Susana Banerjee (MBBS MA PhD FRCP), a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and Professor in Women’s Cancers at the Institute of Cancer Research, as Chief Investigator of the OVACT trial.

Dr. Klaus Edvardsen, MD, Chief Medical Officer of Epitopea, commented, "We are excited by the achievement of this significant regulatory milestone, which is a credit to our dedicated clinical and wider Epitopea team. We also welcome Professor Banerjee to her role as Chief Investigator of our first clinical trial. Her world-class expertise in ovarian cancer and leadership in global clinical development will bring invaluable insights as we transition to a clinical-stage company."

OVACT is a Phase 1/1b dose escalation and expansion trial designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype high-grade serous ovarian cancer patients.

High-Grade Serous Ovarian Cancer(HGSOC) remains one of the most difficult-to-treat solid tumors, with most patients (~80%) presenting with advanced or metastatic disease. While most women respond to first-line platinum chemotherapy, nearly all ultimately relapse and progress to platinum-resistant disease. Existing maintenance options leave a major therapeutic gap among HRP+/BRCA-wildtype patients, who represent roughly half of the ovarian cancer population.

Professor Banerjee added: "There is a substantial unmet need in homologous recombination proficient (HRP) ovarian cancer, where available maintenance therapies deliver limited durable benefit. Epitopea’s CryptiVax-1001 vaccine, which targets a novel repertoire of tumor-specific antigens, has the potential to meaningfully extend remission for patients with few effective treatment options."

Epitopea’s pipeline is enabled by CryptoMapTM, a proprietary discovery engine that identifies tumor-presented antigens arising from the dark genome, a previously inaccessible source of novel, tumor-specific targets. These antigens, known as CryptigensTM, demonstrate high inter-patient sharing, enabling development of true off-the-shelf mRNA immunotherapies.

(Press release, Epitopea, APR 23, 2026, View Source [SID1234664720])